- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2007 (2007), Article ID 43418, 5 pages
Role of p53 and CDKN2A Inactivation in Human Squamous Cell Carcinomas
Phototherapy Unit, San Gallicano Dermatological Institute–IRCCS, Via Elio Chianesi 53, Rome 00144, Italy
Received 15 December 2006; Accepted 26 February 2007
Academic Editor: Honnavara N. Ananthaswamy
Copyright © 2007 Alessia Pacifico and Giovanni Leone. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- T. L. Diepgen and V. Mahler, “The epidemiology of skin cancer,” British Journal of Dermatology, vol. 146, no. 61 supplement, pp. 1–6, 2002.
- M. Alam and D. Ratner, “Cutaneous squamous-cell carcinoma,” New England Journal of Medicine, vol. 344, no. 13, pp. 975–983, 2001.
- N. Soufir, J. P. Molès, and C. Vilmer, et al., “p16 UV mutations in human skin epithelial tumors,” Oncogene, vol. 18, no. 39, pp. 5477–5481, 1999.
- N. Soufir, L. Daya-Grosjean, and P. de La Salmonière, et al., “Association between INK4a-ARF and p53 mutations in skin carcinomas of xeroderma pigmentosum patients,” Journal of the National Cancer Institute, vol. 92, no. 22, pp. 1841–1847, 2000.
- D. J. Leffell, “The scientific basis of skin cancer,” Journal of the American Academy of Dermatology, vol. 42, no. 1, supplement 1, pp. S18–S22, 2000.
- M. L. Kripke, “Immunological effects of ultraviolet radiation,” Journal of Dermatology, vol. 18, no. 8, pp. 429–433, 1991.
- F. R. de Gruijl, H. J. van Kranen, and L. H. F. Mullenders, “UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer,” Journal of Photochemistry and Photobiology B: Biology, vol. 63, no. 1–3, pp. 19–27, 2001.
- K. Y. Tsai and H. Tsao, “The genetics of skin cancer,” American Journal of Medical Genetics, vol. 131C, no. 1, pp. 82–92, 2004.
- A. J. Nataraj, J. C. Trent, and H. N. Ananthaswamy, “p53 gene mutations and photocarcinogenesis,” Photochemistry and Photobiology, vol. 62, no. 2, pp. 218–230, 1995.
- A. S. Jonason, S. Kunala, and G. J. Price, et al., “Frequent clones of p53-mutated keratinocytes in normal human skin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 24, pp. 14025–14029, 1996.
- R. J. W. Berg, H. J. van Kranen, and H. G. Rebel, et al., “Early p53 alterations in mouse skin carcinogenesis by UVB radiation: immunohistochemical detection of mutant p53 protein in clusters of preneoplastic epidermal cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 1, pp. 274–278, 1996.
- H. N. Ananthaswamy, S. M. Loughlin, P. Cox, R. L. Evans, S. E. Ullrich, and M. L. Kripke, “Sunlight and skin cancer: inhibition of p53 mutations in UV-irradiated mouse skin by sunscreens,” Nature Medicine, vol. 3, no. 5, pp. 510–514, 1997.
- R. A. Weinberg, “The retinoblastoma protein and cell cycle control,” Cell, vol. 81, no. 3, pp. 323–330, 1995.
- L. Chin, J. Pomerantz, and R. A. Depinho, “The INK4a/ARF tumor suppressor: one gene—two products—two pathways,” Trends in Biochemical Sciences, vol. 23, no. 8, pp. 291–296, 1998.
- V. O. Melnikova and H. N. Ananthaswamy, “Cellular and molecular events leading to the development of skin cancer,” Mutation Research, vol. 571, no. 1-2, pp. 91–106, 2005.
- N. Soufir, M. Ribojad, and T. Magnaldo, et al., “Germline and somatic mutations of the INK4a-ARF gene in a xeroderma pigmentosum group C patient,” Journal of Investigative Dermatology, vol. 119, no. 6, pp. 1355–1360, 2002.
- V. L. Brown, C. A. Harwood, T. Crook, J. G. Cronin, D. R. Kelsell, and C. M. Proby, “ and tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma,” Journal of Investigative Dermatology, vol. 122, no. 5, pp. 1284–1292, 2004.
- V. Dulic, W. K. Kaufmann, and S. J. Wilson, et al., “p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest,” Cell, vol. 76, no. 6, pp. 1013–1023, 1994.
- M. S. Sheikh, Y. Q. Chen, M. L. Smith, and A. J. Fornace Jr., “Role of in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells,” Oncogene, vol. 14, no. 15, pp. 1875–1882, 1997.
- A. J. Levine, “p53, the cellular gatekeeper for growth and division,” Cell, vol. 88, no. 3, pp. 323–331, 1997.
- D. P. Lane, “p53, guardian of the genome,” Nature, vol. 358, no. 6381, pp. 15–16, 1992.
- M. Hollstein, D. Sidransky, B. Vogelstein, and C. C. Harris, “p53 mutations in human cancers,” Science, vol. 253, no. 5015, pp. 49–53, 1991.
- H. N. Ananthaswamy, S. M. Loughlin, S. E. Ullrich, and M. L. Kripke, “Inhibition of UV-induced p53 mutations by sunscreens: implications for skin cancer prevention,” Journal of Investigative Dermatology Symposium Proceedings, vol. 3, no. 1, pp. 52–56, 1998.
- D. E. Brash, J. A. Rudolph, and J. A. Simon, et al., “A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 22, pp. 10124–10128, 1991.
- S. Bolshakov, C. M. Walker, and S. S. Strom, et al., “p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas,” Clinical Cancer Research, vol. 9, no. 1, pp. 228–234, 2003.
- A. Ouhtit, A. Gorny, H. K. Muller, L. L. Hill, L. Owen-Schaub, and H. N. Ananthaswamy, “Loss of fas-ligand expression in mouse keratinocytes during UV carcinogenesis,” American Journal of Pathology, vol. 157, no. 6, pp. 1975–1981, 2000.
- V. O. Melnikova, A. Pacifico, S. Chimenti, K. Peris, and H. N. Ananthaswamy, “Fate of UVB-induced p53 mutations in SKH-hr1 mouse skin after discontinuation of irradiation: relationship to skin cancer development,” Oncogene, vol. 24, no. 47, pp. 7055–7063, 2005.
- F. J. Stott, S. Bates, and M. C. James, et al., “The alternative product from the human CDKN2A locus, , participates in a regulatory feedback loop with p53 and MDM2,” EMBO Journal, vol. 17, no. 17, pp. 5001–5014, 1998.
- M. Serrano, H.-W. Lee, L. Chin, C. Cordon-Cardo, D. Beach, and R. A. DePinho, “Role of the INK4a locus in tumor suppression and cell mortality,” Cell, vol. 85, no. 1, pp. 27–37, 1996.
- J. G. Herman, C. I. Civin, J.-P. J. Issa, M. I. Collector, S. J. Sharkis, and S. B. Baylin, “Distinct patterns of inactivation of and characterize the major types of hematological malignancies,” Cancer Research, vol. 57, no. 5, pp. 837–841, 1997.
- Z. Saridaki, T. Liloglou, A. Zafiropoulos, E. Koumantaki, O. Zoras, and D. A. Spandidos, “Mutational analysis of CDKN2A genes in patients with squamous cell carcinoma of the skin,” British Journal of Dermatology, vol. 148, no. 4, pp. 638–648, 2003.
- K. Murao, Y. Kubo, N. Ohtani, E. Hara, and S. Arase, “Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways,” British Journal of Dermatology, vol. 155, no. 5, pp. 999–1005, 2006.